Trial Profile
Faslodex Post Marketing Surveillance.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2014
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 09 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned end date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 16 Mar 2009 Actual initiation date changed from Mar 2009 to Feb 2009 as reported by ClinicalTrials.gov.